Mordor Intelligence 分析师预测，亚太肝癌市场将在 2016-2021 年的基础上以 7-15% 的复合年增长率增长。2015 年市场目前的价值为 1.41 亿美元。
由于老年人口的增加，亚洲代表了增长最快的肝癌治疗市场。肝脏具有显着的再生和维持老年人功能的能力。然而，衰老过程中细胞和生理功能的变化会抑制肝脏的正常功能，最终导致疾病。此外，亚洲拥有强大的肿瘤学市场之一，占全球所有新癌症病例的近一半。这些增加的癌症病例还包括肝癌。亚洲国家越来越多的肝癌病例需要大量的药物来预防和治疗肝癌和肿瘤。
由于市场上只有少数获批药物和其他几个正在筹备中，事实证明，全球范围内该病的发病率和死亡率持续上升。许多新的靶向疗法有望在未来几年内进入市场。靶向癌症疗法使用药物通过中断某些被称为分子靶标的分子来防止癌细胞的扩张，从而阻止癌细胞的进展和生长。这种治疗也被称为“分子靶向治疗”，专注于细胞和分子的变化，特别是与癌症有关。因此，与包括放射疗法和化学疗法在内的其他癌症治疗方法相比，它更有效。
亚太肝癌市场的细分基于：
该行业的一些主要参与者包括 Bayer Schering Pharma AG、Onyx Pharmaceuticals, Inc.、Celsion Corp.、Alnylam Pharmaceuticals, Inc.、ArQule, Inc.、4SC AG、ImClone Systems Inc.、Jennerex Biotherapeutics, Inc.、辉瑞Inc.、F. Hoffmann-La Roche Ltd. 和 Bristol-Myers Squibb Company。等等。
驱动程序：
约束：
本报告的特点
报告内容
1. Executive Summary
2. Research Methodology
3. Introduction
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 aging population
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 high unmet needs for the treatment of liver cancer
4.2.4 excessive alcohol consumptions
4.3 Market Restraints
4.3.1 Techinical Advancements
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.3.4 Low success rate in clinical trails for cancer drugs
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Type
6.1.1 primary liver cancer
6.1.1.1 Hepatocellular carcinoma (HCC)
6.1.1.2 Angiosarcoma
6.1.1.3 Cholangiocarcinoma (bile duct cancer)
6.1.1.4 Hepatoblastoma
6.1.2 secondary liver cancer
6.1.3 Benign liver growths
6.2 Diagnosis
6.2.1 ultrasound scans
6.2.2 Confirmatory Needle biopsy
6.2.3 Endoscopic Ultrasound
6.2.4 Laparoscopy
6.2.5 CT Scan
6.2.6 PET Scan
6.2.7 magnetic resonance imaging (MRI) scans
6.3 Therapeutics
6.3.1 Hepatocellular carcinoma
6.3.2 Cholangiocarcinoma
6.3.3 Hepatoblastoma
6.3.4 Targeted therapy
6.3.5 Others
6.4 By End User
6.4.1 Pediatrics
6.4.2 Adults
6.5 By Geography
6.5.1 China
6.5.2 India
6.5.3 Japan
6.5.4 Australia
6.5.5 Singapore
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 Bayer Schering Pharma AG,
8.2 Onyx Pharmaceuticals, Inc., Celsion Corp.,
8.3 Alnylam Pharmaceuticals, Inc.,
8.4 ArQule, Inc.,
8.5 4SC AG,
8.6 ImClone Systems Inc.,
8.7 Jennerex Biotherapeutics, Inc.,
8.8 Pfizer Inc.,
8.9 F Hoffmann-La Roche Ltd..,
8.10 Bristol-Myers Squibb Company.
9. Appendix
9.1 Abbrevations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer
